The FDA’s top drug regulator was placed on administrative leave after blowing the whistle on a controversial new approval process he claims undermines decades of rigorous scientific standards and consolidates dangerous power in the hands of a single official.
Story Overview
- Dr. George Tidmarsh, head of the FDA’s drug evaluation center, was placed on leave after criticizing the new fast-track approval system.
- Tidmarsh alleges retaliation for opposing regulatory changes that bypass traditional scientific review processes.
- The new system grants the Chief Medical Officer, Vinay Prasad, extensive authority over drug approvals.
- FDA creates “toxic environment” according to top regulator who may resign over integrity concerns.
Top FDA Official Challenges New Approval System
Dr. George Tidmarsh, who leads the FDA’s Center for Drug Evaluation and Research, was placed on administrative leave after raising serious concerns about a new regulatory process.
The system uses a tumor board-style review to fast-track drug approvals for “companies aligned with critical U.S. national health priorities.” Tidmarsh warned that this arrangement circumvents the rigorous scientific debate that has protected Americans for decades, representing a fundamental departure from established FDA protocols.
The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague. https://t.co/tm2esMU5wu
— The Daily Beast (@thedailybeast) November 3, 2025
Retaliation Claims Against FDA Leadership
Tidmarsh denied allegations of personal misconduct reported by STAT News and claims his removal constitutes retaliation for opposing Chief Medical Officer Vinay Prasad. He told ABC News the new approval process “puts Vinay Prasad in charge of every drug approval” and would be “different than the entire history of decades of the FDA.”
The timing of his administrative leave, which followed his criticism of the regulatory changes, raises serious questions about whether dissenting voices are being silenced within the agency.
Erosion of Scientific Standards Threatens Public Safety
The controversy highlights broader concerns about maintaining rigorous oversight in drug approval processes that directly impact American lives. Tidmarsh’s allegations suggest the FDA is abandoning time-tested scientific review methods in favor of a system that concentrates approval authority in fewer hands.
This represents exactly the kind of government overreach and erosion of institutional safeguards that undermines public trust and potentially endangers citizens who depend on thorough drug safety evaluations.
Secretary Kennedy’s office stated expectations of “highest ethical standards,” while Tidmarsh continues to weigh resigning from what he describes as a “toxic” environment that is “bad for the American people.”
His potential departure would remove a key voice advocating for traditional scientific rigor at a time when the agency faces questions about its commitment to established safety protocols.
